ACADIA Pharmaceuticals to Expand Scandinavian Chemistry Operations

03-Sep-2004

ACADIA Pharmaceuticals Inc. and Medeon Science Park announced plans to establish a modern chemistry research and development facility in Malmo, Sweden. The new laboratory, under construction by Medeon Fastigheter AB, is centrally located within the Medicon Valley region, home to greater than 60 per cent of Scandinavian pharmaceutical and biotechnology companies.

ACADIA's biological research and clinical development activities are conducted at the company's headquarters in San Diego, California. Since 1997, ACADIA has maintained its chemistry research operations in the Copenhagen region. ACADIA intends to occupy the new 3000 m2 custom-built chemistry laboratory to support expansion of its proprietary drug discovery activities, while continuing to maintain a Danish presence.

"Over the past seven years, ACADIA has successfully built an outstanding chemistry research subsidiary in Denmark and with the establishment of this new facility, we will be able to continue to grow our Scandinavian operations," said Bo-Ragnar Tolf, Ph.D., vice president, chemistry and managing director of Danish subsidiary ACADIA Pharmaceuticals A/S. "The Malmo site, with its ideal location at the Medeon Science Park, should give us great visibility and access to a growing scientific talent pool in the Medicon Valley region."

"We view ACADIA's choice of Medeon and Malmo as confirmation that the city is attractive for knowledge-intensive companies," remarked Ilmar Reepalu, the municipal financial commissioner in Malmo. "For a couple years now, Malmo has been expending considerable effort to create optimal conditions for innovative entrepreneurship."

https://www.chemeurope.com/en/news/39408/acadia-pharmaceuticals-to-expand-scandinavian-chemistry-operations.html